EPCAM and breast carcinoma: In this study, we investigated the ability of EpMab-37-mG2a-f to induce ADCC, CDC, and antitumor activities against a breast cancer cell line (BT-474) derived from the luminal B HER2-positive subtype [34], and a pancreatic cancer cell line (Capan-2), both of which express EpCAM.